Oramed Pharmaceuticals (ORMP) Equity Ratio (2011 - 2026)

Oramed Pharmaceuticals has reported Equity Ratio for 16 years, with the latest figure at 0.89 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 6.53% year-over-year to 0.89; the trailing twelve-month figure through Mar 2026 stood at 0.89 (down 6.53% YoY), and the FY2025 full-year result was 0.87, down 7.57% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.89, up from 0.87 in the prior quarter.
• The five-year high for Equity Ratio was 0.96 in Q2 2023, with the low at 0.64 in Q3 2023.
• Historically, Equity Ratio has averaged 0.9 across 5 years, with a median of 0.94 in 2024.
• Annual changes were most pronounced in 2023 — Equity Ratio slumped 31.07% — and 2024, when it jumped 46.75%.
• Oramed Pharmaceuticals' Equity Ratio stood at 0.94 in 2022, then retreated by 21.02% to 0.74 in 2023, then grew by 26.74% to 0.94 in 2024, then retreated by 7.57% to 0.87 in 2025, then advanced by 2.44% to 0.89 in 2026.
• The last three Equity Ratio figures came in at 0.89 (Q1 2026), 0.87 (Q4 2025), and 0.92 (Q3 2025), per Business Quant data.